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Research Article
The GPR120 agonist TUG-891 promotes metabolic
health by stimulating mitochondrial respiration in
brown fat
Maaike Schilperoort1,2,3,* , Andrea D van Dam2,3, Geerte Hoeke2,3, Irina G Shabalina4 ,
Anthony Okolo5, Aylin C Hanyaloglu5, Lea H Dib6, Isabel M Mol2,3, Natarin Caengprasath5,
Yi-Wah Chan7, Sami Damak8, Anne Reifel Miller9, Tamer Coskun9, Bharat Shimpukade10,
Trond Ulven10, Sander Kooijman2,3, Patrick CN Rensen2,3 & Mark Christian1,**
Abstract
Brown adipose tissue (BAT) activation stimulates energy expendi-
ture in human adults, which makes it an attractive target to
combat obesity and related disorders. Recent studies demonstrated
a role for G protein-coupled receptor 120 (GPR120) in BAT thermo-
genesis. Here, we investigated the therapeutic potential of GPR120
agonism and addressed GPR120-mediated signaling in BAT. We
found that activation of GPR120 by the selective agonist TUG-891
acutely increases fat oxidation and reduces body weight and fat
mass in C57Bl/6J mice. These effects coincided with decreased
brown adipocyte lipid content and increased nutrient uptake by
BAT, confirming increased BAT activity. Consistent with these obser-
vations, GPR120 deficiency reduced expression of genes involved in
nutrient handling in BAT. Stimulation of brown adipocytes in vitro
with TUG-891 acutely induced O2 consumption, through GPR120-
dependent and GPR120-independent mechanisms. TUG-891 not
only stimulated GPR120 signaling resulting in intracellular calcium
release, mitochondrial depolarization, and mitochondrial fission,
but also activated UCP1. Collectively, these data suggest that acti-
vation of brown adipocytes with the GPR120 agonist TUG-891 is a
promising strategy to increase lipid combustion and reduce obesity.
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Introduction
Brown adipose tissue (BAT) is present and active in human adults
and contributes to total energy expenditure (EE) (Cypess et al, 2009;
van Marken Lichtenbelt et al, 2009; Virtanen et al, 2009). This
contrasts with white adipose tissue (WAT), which primarily serves
as a site of energy storage. Cold exposure, the natural stimulus of
BAT, increases the volume and activity of metabolically active BAT
and reduces fat mass in adult human subjects (van der Lans et al,
2013; Yoneshiro et al, 2013; Blondin et al, 2014). Cold exposure
stimulates the sympathetic nervous system to release nore-
pinephrine, which in turn activates brown adipocytes through the
b3-adrenergic receptor (ADRB3) (Argyropoulos & Harper, 2002).
Activation of brown adipocytes initiates intracellular signaling
cascades, resulting in the breakdown of triglycerides (TG) stored in
intracellular lipid droplets to yield fatty acids (FA) and glycerol
(Cannon & Nedergaard, 2004). The FAs are subsequently trans-
ported to the mitochondria where they are either oxidized or used
to allosterically activate uncoupling protein-1 (UCP1), which is
present in the inner membrane of mitochondria (Fedorenko et al,
2012; Nicholls, 2017). UCP1 disrupts the proton gradient that is
required for ATP synthesis, resulting in the release of energy as heat
instead of ATP: a process called thermogenesis (Trayhurn, 2017).
Since activated BAT burns high amounts of FAs, it is considered an
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attractive target to combat obesity and related disorders. Therefore,
novel targets to increase BAT activity are highly warranted.
A potential target is G protein-coupled receptor 120 (GPR120), also
termed free FA receptor 4 (FFAR4). We have previously shown that
GPR120 is highly expressed in BAT and cold exposure further increases
its expression in both BAT and subcutaneous WAT of mice (Rosell
et al, 2014), suggesting that GPR120 contributes to the thermogenic
capacity of BAT. GPR120 is activated by both medium-chain
FA (MCFA) and long-chain FA (LCFAs) (Hirasawa et al, 2005;
Christiansen et al, 2015) and is coupled to Gaq, which activates
several intracellular signaling pathways. Recent studies have revealed
that through these signaling mechanisms, GPR120 plays an important
role in energy metabolism, hormonal regulation, and the immune
system. For example, Oh et al (2010) demonstrate that GPR120 medi-
ates the anti-inflammatory actions of x-3 FAs. GPR120 deficiency leads
to obesity, glucose intolerance, and hepatic steatosis in mice fed a
high-fat diet (Ichimura et al, 2012). In humans, GPR120 expression is
higher in obese compared to lean subjects, and individuals carrying a
mutation associated with decreased GPR120 signaling have an
increased risk of obesity (Ichimura et al, 2012). Given the high
GPR120 expression in BAT, it is likely that BAT contributes to the
metabolic effects of GPR120 observed in these studies. Indeed, a very
recent study by Quesada-Lo´pez et al (2016) confirmed a role for
GPR120 in BAT activation. However, therapeutic potential and under-
lying signaling of GPR120-mediated BAT activation remain to be
elucidated.
Therefore, the aims of this study were to further investigate the ther-
apeutic potential of GPR120 agonism and to address GPR120-mediated
intracellular signaling in BAT. We found that stimulation of GPR120 by
the agonist TUG-891 increases fat oxidation and lipid uptake by BAT
thereby reducing fat mass, while GPR120 deficiency reduces expression
of genes involved in nutrient handling. Mechanistically, we show that
TUG-891 acts in a GPR120-dependent manner to induce intracellular
Ca2+ release which could result in mitochondrial depolarization and
fragmentation. In addition, our data reveal that TUG-891 activates
mitochondrial UCP1, which may act synergistically with mitochondrial
fragmentation to increase respiration. Taken together, our data indicate
that by acutely increasing lipid combustion by BAT, GPR120 agonism
may be a promising therapeutic strategy to reduce obesity.
Results
The GPR120 agonist TUG-891 increases lipid oxidation and
reduces fat mass in mice
To investigate the effect of GPR120 activation on energy metabolism
in vivo, mice were injected with the GPR120 agonist TUG-891 daily
for a period of 2.5 weeks. This compound was selected due to
higher selectivity for GPR120 over GPR40 compared to other
agonists, including GW9508 and NCG21 (Shimpukade et al, 2012;
Hudson et al, 2013). TUG-891 reduced total body weight (Fig 1A),
which was due to a large reduction in fat mass (73%; Fig 1B) and
a minor reduction in lean mass (9.9%; Fig 1C) at week 2.5
compared to vehicle. The reduced lean mass could be due to
increased muscle turnover, as TUG-891 non-significantly increased
expression of markers for both muscle atrophy and regeneration
(Appendix Fig S1). During the first week of treatment, food intake
was similar in the control and treatment groups (Fig 1D), while fat
mass was already reduced by 19% in the TUG-891-treated group at
day 5. Longer treatment reduced food intake, which further contrib-
uted to body weight and fat mass loss. To investigate whether TUG-
891 enhances EE or alters substrate utilization, mice were housed in
metabolic cages during the first week of treatment. TUG-891 treat-
ment did not increase total EE (Appendix Fig S2A) nor did it affect
physical activity levels (Appendix Fig S2B). However, TUG-891
acutely lowered the respiratory exchange ratio (RER) upon injec-
tion, which persisted throughout the dark period (Fig 1E). Accord-
ingly, TUG-891 lowered glucose oxidation (Fig 1F) and largely
increased fat oxidation (Fig 1G). This increase in fat oxidation was
supported by histological analysis of adipose tissues, revealing that
TUG-891 administration reduced lipid content in BAT (28%;
Fig 2A), and adipocyte size in both sWAT (47%; Fig 2B) and
gWAT (38%; Fig 2C). In addition, total organ weights of iBAT
(31%), gWAT (44%), and liver (14%) were reduced in TUG-
891-treated mice as compared to controls (Fig 2D). Plasma TG
levels were increased at the end of the study, possibly as a result of
increased lipolysis (Appendix Fig S3A). Protein (Appendix Fig S3B–
E) and gene (Appendix Fig S3F) expressions of markers for lipolysis,
adipogenesis, proliferation, and thermogenesis were largely unaf-
fected in BAT. However, Ucp1 gene expression (Appendix Fig S3H)
and protein staining (Appendix Fig S4) were increased in gWAT of
TUG-891-treated animals, suggesting GPR120-mediated browning.
As TUG-891 also has affinity for GPR40 (Hudson et al, 2013), we
aimed to confirm that the effects of TUG-891 on body composition
and substrate utilization were mediated by GPR120. To this end,
metabolic effects of TUG-891 were also assessed in GPR120 KO mice
and WT littermates. In GPR120 KO mice, TUG-891 non-significantly
reduced body weight (Fig 3A) and fat mass (Fig 3B), but not to the
same extent as in WT mice. TUG-891 decreased food intake simi-
larly in WT and GPR120 KO mice (Fig 3C). The modest decrease in
fat mass in TUG-891 GPR120 KO mice compared to non-treated WT
mice may be related to diminished food intake. Lean mass was
unchanged in all treatment groups (Fig 3D). In addition, while RER
and fat oxidation did not differ between WT and GPR120 KO mice
at baseline (Appendix Fig S5), TUG-891 non-significantly
(P = 0.136) decreased RER (Fig 3E) and increased fat oxidation
(Fig 3F) during the dark period in WT mice but not in GPR120 KO
mice.
The GPR120 agonist TUG-891 stimulates fatty acid uptake by BAT
Hereafter, we aimed to elucidate which organs were responsible for
the increased fat oxidation in TUG-891-treated WT animals. As
increased fat oxidation subsequently leads to increased FA uptake,
the tissue-specific uptake of FAs derived from intravenously injected
lipoprotein-like particles labeled with glycerol tri[3H]oleate was
determined. In WT mice, TUG-891 treatment markedly increased
the uptake of [3H]oleate in both iBAT and subscapular BAT (sBAT)
as compared to vehicle (Fig 4A), suggesting increased BAT activity.
TUG-891 also increased the uptake of [14C]deoxyglucose in iBAT
and sBAT (Fig 4B). However, when the uptake data were corrected
for organ weight (for organs that could be removed quantitatively
within an acceptable time frame), the difference in glucose uptake
was lost. FA uptake in whole iBAT remained approximately twice
as high in treated WT mice versus controls (Appendix Fig S6),
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Figure 1. The GPR120 agonist TUG-891 decreases body weight and fat mass, and increases fat oxidation.
A–D C57Bl/6J mice on chow diet were treated with the GPR120 agonist TUG-891 (35 mg/kg) or vehicle (n = 8) for 2.5 weeks. Body weight, fat mass, lean mass, and food
intake were measured at indicated time points.
E–G Vehicle- and TUG-891-treated mice (n = 8) were housed in fully automated metabolic cages in which respiratory exchange ratio (RER) (E), glucose oxidation (F),
and fat oxidation (G) were measured. Injection of the GPR120 agonist TUG-891 (35 mg/kg) or vehicle is indicated by dotted lines, and light and gray areas represent
the light and dark phase, respectively. For bar graph analysis, mean results in light and dark phase were calculated.
Data information: Data represent means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the vehicle group, according to the two-tailed unpaired Student’s
t-test. The exact P-value for each significant difference can be found in Appendix Table S5.
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Figure 2. TUG-891 decreases lipid content of BAT and WAT.
A–C Representative images of hematoxylin and eosin (H&E)-stained interscapular BAT (iBAT), subcutaneous WAT (sWAT), and gonadal WAT (gWAT) of mice treated with
vehicle or the GPR120 agonist TUG-891 (n = 8). Stained slides were digitalized, and lipid droplet content of BAT and adipocyte size in WAT was analyzed using
ImageJ software.
D After mice treated with vehicle or the GPR120 agonist TUG-891 (n = 8) were sacrificed, iBAT, gWAT, and liver were collected and weighed (n = 8).
Data information: Data represent means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the vehicle group, according to the two-tailed unpaired Student’s
t-test. The exact P-value for each significant difference can be found in Appendix Table S5.
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Figure 3. Metabolic effects of TUG-891 are reduced or absent in GPR120-deficient mice.
A–D GPR120 KO mice and WT littermates (n = 6–8) were treated with the GPR120 agonist TUG-891 (35 mg/kg) or vehicle for 12 days. At the beginning (day 0) and end
(day 12) of this treatment period, body weight, fat mass, and lean mass were measured. Food intake was determined after 5 and 12 days of treatment.
E–F GPR120 KO mice and WT littermates (n = 6–8) were treated with the GPR120 agonist TUG-891 (35 mg/kg) or vehicle. Respiratory exchange ratio (RER) and fat
oxidation were determined by housing the mice in metabolic cages. Injection of TUG-891 or vehicle is indicated by dotted lines, and light and gray areas represent
the light and dark phase, respectively. For bar graph analysis, mean results in the light and dark phase were calculated.
Data information: Data represent means  SEM. *P < 0.05, **P < 0.01 compared to the vehicle group, according to two-way ANOVA with Tukey’s post hoc test. The
exact P-value for each significant difference can be found in Appendix Table S5.
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showing an independency of organ weight. In line with these data,
TUG-891 decreased total organ weights of iBAT and sWAT depots
as compared to vehicle in WT mice, but not in GPR120 KO mice
(Fig 4C).
GPR120 alters expression of genes involved in nutrient handling
To evaluate how GPR120 modulates lipid handling by BAT, we
investigated the effects of GPR120 deficiency on the global gene
expression profile in BAT by performing a microarray on BAT of
GPR120 KO and WT littermates. Clustering of genes was observed
between GPR120 KO and WT mice (Fig 5A). The top 50 of genes
that were either upregulated or downregulated in the absence of
GPR120 are listed in Appendix Table S3. Selected genes were vali-
dated, and expression of genes associated with inflammation
(Fig 5B), adipocyte biology (Fig 5C), glucose metabolism (Fig 5D),
and lipid metabolism (Fig 5E) was investigated by qRT–PCR.
Expression of inflammatory genes tended to be increased in GPR120
KO BAT. GPR120 deficiency upregulated Sncg, encoding synuclein-c
which is involved in lipid droplet dynamics in white adipocytes and
is negatively regulated by PPARc (Dunn et al, 2015). On the other
hand, GPR120 deficiency downregulated Mlxipl, which encodes the
carbohydrate response element-binding protein (ChREBP), a tran-
scriptional inducer of glucose metabolism and de novo lipogenesis
(Witte et al, 2015). Of the genes associated with glucose metabo-
lism, Glut4, Insr, Adcy4, and Gys2 were downregulated in GPR120
KO BAT. Gys2 encodes glycogen synthase 2 and is PPARc-regulated
in adipocytes (Mandard et al, 2007). Of the genes that determine
lipid metabolism, those involved in both lipogenesis (Acc1, Acc2,
Fas, Scd2) and intracellular lipolysis (Hsl, Atgl, Pnpla3) were lower
in GPR120 KO BAT.
Functional annotation clustering using DAVID (https://david.
ncifcrf.gov/) (Dennis et al, 2003) revealed that genes downregu-
lated in the absence of GPR120 were associated with mitochondrial
function, FA metabolism, nucleotide binding, and mRNA process-
ing (Appendix Table S4). The set of upregulated genes was associ-
ated with immune responses, as well as antigen processing and
ribosomes.
Gpr120 expression promotes brown adipocyte differentiation
and is increased in “browned” white adipocytes
Using a conditionally immortalized model of brown adipocytes
(Rosell et al, 2014), we investigated the expression profile of Gpr120
in preadipocytes differentiated to fully mature adipocytes over
7 days. Like Ucp1 expression, Gpr120 expression was highly
induced during differentiation of brown adipocytes, reaching maxi-
mum levels on day 6 (Fig 6A). This is consistent with high GPR120
expression in BAT compared to other organs (Appendix Fig S7).
Treatment of differentiated adipocytes with the b3-adrenergic
agonist CL induced both Gpr120 (ninefold) and Ucp1 (53-fold)
expression (Fig 6A). Differentiation also increased expression of
adipocyte markers aP2, Cidea, and Adrb3, and decreased expression
of the preadipocytes marker Pref1, validating our brown adipocyte
cell line (Appendix Fig S8).
As we previously reported that Gpr120 was induced by cold
exposure in white adipose tissue (Rosell et al, 2014), we next inves-
tigated whether in vitro browning of white adipocytes with
rosiglitazone treatment (resulting in so called “brite” adipocytes)
could similarly enhance gene expression. Unlike Ucp1 that was
induced by CL in brown, white, and brite adipocytes, Gpr120
expression was not increased by CL treatment in white and brite
adipocytes (Fig 6B). However, basal expression of Gpr120 in dif-
ferentiated brite adipocytes was increased as compared to white
adipocytes, indicating a potential role of Gpr120 in browning of
white adipocytes.
To study whether GPR120 is directly involved in adipocyte dif-
ferentiation, brown adipocyte cell lines were generated from WT and
GPR120 KO mice. Both cell lines differentiated to mature brown
adipocytes when exposed to a standard hormone differentiation treat-
ment. However, GPR120 KO adipocytes accumulated a lower amount
of lipids as evidenced by Oil Red O staining (Fig 6C) and exhibited
lower expression of the adipocyte differentiation marker aP2 and
Ucp1 (Fig 6D), suggesting impaired differentiation in GPR120 KO
cells. Treatment with TUG-891 throughout differentiation tended to
increase Ucp1 expression in WT but not GPR120 KO cells (Fig 6D).
TUG-891 directly activates brown adipocytes in vitro through
UCP1 activation and mitochondrial fragmentation
To investigate whether the GPR120 agonist TUG-891 directly acti-
vates brown adipocytes and to study the downstream intracellular
signaling pathways involved, we stimulated differentiated brown
adipocytes with TUG-891. Strikingly, TUG-891 acutely increased the
O2 consumption rate (OCR) of brown adipocytes by more than
twofold (Fig 7A). Pretreatment with the GPR120 antagonist AH7614
reduced rather than abolished this response (Fig 7A), indicating that
TUG-891 exhibits both GPR120-dependent and GPR120-independent
activity. We investigated whether TUG-891 functions in a manner
similar to LCFAs which can directly activate UCP1 by measuring O2
consumption in isolated BAT mitochondria in conditions mimicking
a cellular environment with high purine nucleotide (GDP) content
and inhibited UCP1 (Matthias et al, 2000). Indeed, TUG-891
(≥ 10 lM) increased O2 consumption in mitochondria isolated from
WT mice (Fig 7B), suggesting that TUG-891 has the capacity to
overcome purine nucleotide inhibition and activate UCP1 in brown
adipocytes. TUG-891 also increased O2 consumption in mitochon-
dria from UCP1 KO mice, but this effect was smaller and occurred at
higher concentrations (≥ 90 lM) as compared to WT mitochondria
(Fig 7C), a response that is also observed with oleate (Shabalina
et al, 2004). As oxidative capacity (FCCP response, Fig 7B and C) of
WT and UCP1 KO mitochondria was equal, these results suggest
that TUG-891 increases mitochondrial respiration through activation
of UCP1 (Appendix Fig S9A). TUG-891 exhibited a competitive inter-
action with GDP in WT but not UCP1 KO mitochondria
(Appendix Fig S9B and C), further supporting the effect of TUG-891
on UCP1.
Next, we investigated GPR120-dependent effects of TUG-891 by
examining potential downstream targets of G protein signaling that
could partly mediate the TUG-891-induced O2 consumption in
brown adipocytes. To ensure that GPR120 is Gaq-coupled and does
not signal via Gas in brown adipocytes, the effect of TUG-891 on
intracellular cAMP levels was determined. As expected, TUG-891
had no effect on cAMP production (Appendix Fig S9D). As for Gaq
targets, TUG-891 increased the amount of phosphorylated ERK
and AKT (Appendix Fig S9E). However, pretreatment of brown
EMBO Molecular Medicine e8047 | 2018 ª 2018 The Authors
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adipocytes with the MEK inhibitor U0126 (Appendix Fig S9F) or an
AKT 1/2 kinase inhibitor (Appendix Fig S9G) did not reduce O2
consumption, excluding requirement of the ERK and AKT pathways
for this effect. Pretreatment with the cell-permeable Ca2+ chelator
BAPTA-AM strongly reduced the TUG-891-induced O2 consumption
(Fig 7D), indicating that intracellular Ca2+ is essential for GPR120-
mediated activation of brown adipocytes. Indeed, TUG-891 strongly
increased intracellular Ca2+ concentrations (Fig 7E). This effect was
absent in adipocytes preincubated with the GPR120 antagonist
AH7614 and in GPR120 KO adipocytes (Fig 7E), confirming GPR120
dependency. The Gaq inhibitor YM-254890 also blocked the Ca2+
response (Appendix Fig S9H), indicating that this effect of GPR120
activation is indeed mediated via Gaq signaling. As Ca2+ could
affect mitochondrial polarization, effects of TUG-891 on mitochon-
drial membrane potential were investigated. Cells were incubated
with MitoTracker Green FM (MTG) and MitoTracker Red CMXRos
(MTR), which stain mitochondria independent of and dependent on
membrane potential, respectively. Relative intensity (MTR/MTG) of
these stainings can be used as a measure for mitochondrial polariza-
tion. Stimulation with TUG-891 resulted in fading of the MTR signal
A
B
C
Figure 4. TUG-891 increases the uptake of nutrients by BAT.
A, B WT and GPR120 KO mice (n = 6–8) treated with vehicle or the GPR120 agonist TUG-891 were intravenously injected with [3H]TO-labeled lipoprotein-like emulsion
particles and [14C]deoxyglucose ([14C]DG). After 15 min, mice were sacrificed and uptake of [3H]TO- and [14C]DG-derived radioactivity per gram tissue was
determined in various organs, including gonadal WAT (gWAT), subcutaneous WAT (sWAT), interscapular BAT (iBAT), and subscapular BAT (sBAT).
C After WT and GPR120 KO mice (n = 6–8) treated with vehicle or the GPR120 agonist TUG-891 were sacrificed, organs were collected and weighed.
Data information: Data represent means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the vehicle group or indicated control group, according to two-way
ANOVA with Tukey’s post hoc test (A, B) or the two-tailed unpaired Student’s t-test (C). The exact P-value for each significant difference can be found in
Appendix Table S5.
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while the MTG signal remained intense, indicative of mitochondrial
depolarization (Fig 7F). In addition, mitochondria were more frag-
mented following TUG-891 stimulation (Fig 7G), pointing toward
increased mitochondrial fission, which could explain the GPR120-
dependent increase in respiration. Of note, the timing of TUG-891-
induced changes in mitochondrial morphology coincides with
increases in intracellular Ca2+, suggesting this effect is mediated
through Ca2+.
Discussion
In the current study, we aimed to investigate the therapeutic poten-
tial and mechanism of action of GPR120 agonism. We specifically
focussed on BAT and demonstrated that the GPR120 agonist TUG-
891 increases the activity of brown adipocytes, potentially by stimu-
lating Ca2+-induced mitochondrial depolarization and fission. In
addition, TUG-891 may act GPR120 independently to activate UCP1
A B
C
E
D
Figure 5. GPR120 deficiency alters the expression of genes involved in glucose and lipid metabolism in BAT.
A Probe sets for WT and GPR120 KO BAT from microarray analysis are colored according to average expression levels across all samples, with green denoting a higher
expression level and red denoting a lower expression level. The probe sets shown in the heat map passed the threshold of absolute value of the logFC > 0.5 and
P-adjusted < 0.05.
B–E Expression of genes involved in inflammation, adipocyte biology, glucose metabolism, and lipid metabolism in BAT from GPR120 KO mice (n = 5) and WT
littermates (n = 6) was determined through qRT–PCR (N.D. = non-detectable). Data represent means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the
WT control group, according to the two-tailed unpaired Student’s t-test. The exact P-value for each significant difference can be found in Appendix Table S5.
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and increase uncoupled respiration. These mechanisms could have
acted synergistically in vivo to induce BAT activation, thereby
increasing lipid oxidation and reducing fat mass.
We assessed the therapeutic potential of GPR120 activation by
using the agonist TUG-891, a more selective and potent agonist for
GPR120 than a-linolenic acid, GW9508, and NCG21 (Shimpukade
et al, 2012; Hudson et al, 2013). Mice treated with TUG-891 exhib-
ited decreased body weight and fat mass, and an increased fat
oxidation. These results are in line with a previous study that
observed reduced body weight after chronic GPR120 agonist treat-
ment in diet-induced obese mice (Azevedo et al, 2016). The increased
fat oxidation upon TUG-891 treatment suggested involvement of
BAT, as previous studies have demonstrated that selective BAT acti-
vation specifically stimulates lipid oxidation (Berbee et al, 2015;
Schilperoort et al, 2016). Indeed, TUG-891 enhanced the uptake of
TG-derived FA by BAT, indicating an increased lipid combustion in
BAT resulting in a higher need to take up lipids from the circulation.
Moreover, lipid droplet content in iBAT and total iBAT weight were
decreased in TUG-891-treated mice, also a feature of increased BAT
activity. Adipocyte size was decreased in WAT of TUG-891-treated
mice, indicative of increased lipolysis in WAT, possibly to release
lipids into the circulation to fuel the highly active BAT.
To further elucidate the importance of GPR120 for BAT function-
ality, we examined expression patterns of Gpr120 in vivo and
in vitro. We found that Gpr120 is highly expressed in BAT as
compared to other tissues. Furthermore, Gpr120 expression
increased during brown adipocyte differentiation and upon treat-
ment with the classical BAT activator CL (Berbee et al, 2015). This
is in line with previous data showing that cold exposure, the most
potent browning stimulus, increases the expression of Gpr120 in
BAT, sWAT, and gWAT (Rosell et al, 2014). Rosiglitazone, a PPARc
agonist that stimulates browning (Ohno et al, 2012), induced
Gpr120 expression in subcutaneous white adipocytes in vitro. A
similar effect of browning on Gpr120 expression was observed
earlier upon treatment of 3T3-L1 white adipocytes with the PPAR
agonist troglitazone (Gotoh et al, 2007). These results demonstrate
that like Ucp1, Gpr120 is highly expressed in brown adipocytes and
increases during differentiation and browning, signifying an impor-
tant role for Gpr120 in BAT physiology. This is further supported by
reduced lipid accumulation and aP2 expression in GPR120-deficient
adipocytes, indicative of impaired differentiation. The latter findings
concur with previous studies that used siRNA to knockdown Gpr120
expression in 3T3-L1 cells, which resulted in reduced lipid droplet
accumulation and aP2 expression (Gotoh et al, 2007; Liu et al,
2012). The expression of genes involved in glucose and lipid meta-
bolism was reduced in BAT from GPR120-deficient mice, suggesting
that the uptake and handling of nutrients are less efficient in the
absence of GPR120. This is in accordance with the increased uptake
of nutrients by BAT upon GPR120 stimulation by TUG-891.
Our findings that expression of Gpr120 in BAT was highest as
compared to other organs and that Gpr120 expression is induced
upon brown adipocyte differentiation were corroborated by
◀ Figure 6. GPR120 is involved in differentiation of brown adipocytes and browning of white adipocytes.A Immortalized murine brown adipocytes (n = 3) were differentiated for 0, 2, 4, 6, or 7 days after which expression of Gpr120 and Ucp1 was determined by qRT–PCR.
On day 7, a subset of adipocytes (n = 3) was stimulated with CL (10 lM) or vehicle.
B Expression of Gpr120 and Ucp1 was measured in undifferentiated (Undiff), differentiated (Diff), and CL-treated (Diff + CL) brown adipocytes (BA), subcutaneous white
adipocytes (sWA), and sWA treated with the browning agent rosiglitazone (sWA brite) (n = 3).
C WT and GPR120 KO brown adipocytes (n = 3) were treated with vehicle or TUG-891 (10 lM) throughout differentiation and stained at day 0, 3, 7, and 9 of
differentiation with Oil Red O. Absorbance of the staining at 520 nm was quantified. A representative image at day 8 of differentiation was taken with a phase-
contrast microscope (Leica) at 20-fold magnification.
D As in (C), WT and GPR120 KO brown adipocytes (n = 3) were treated with vehicle or TUG-891 throughout differentiation to analyze expression patterns of aP2 and
Ucp1.
Data information: Data represent means  SEM. **P < 0.01 compared to the vehicle group, ***P < 0.001 compared to the WT control group or indicated controls,
according to the two-tailed unpaired Student’s t-test (A) or two-way ANOVA with Dunnett’s post hoc test (B–D). The exact P-value for each significant difference can be
found in Appendix Table S5.
▸Figure 7. TUG-891 increases oxygen consumption by brown adipocytes, mediated by direct UCP1 activation and mitochondrial fragmentation.A Immortalized brown adipocyte (n = 5–6) was pretreated with either vehicle or the GPR120 antagonist AH7614 (100 lM) for 30 min, followed by measurement of
the basal oxygen consumption rate (OCR) for 15 min in a Seahorse XF24 analyzer. Hereafter, cells were treated with either vehicle or the GPR120 agonist TUG-891
(10 lM) and OCR was measured for another 30 min.
B, C Representative traces showing the effects of TUG-891 (heavy line) and vehicle (thin line) on oxygen consumption in BAT mitochondria (0.125 mg/ml) from WT (B)
and UCP1 KO (C) mice (n = 4–5). Additions were mitochondria (M), GDP (1 mM), TUG-891 (successively added in the concentration range of 10–150 lM), and FCCP
(1.0–1.4 lM). The breaks in trace indicate periods of chamber re-oxygenation.
D Immortalized brown adipocytes (n = 5–6) were pretreated for 30 min with vehicle or BAPTA-AM (25 lM), after which the OCR was determined in a Seahorse XF24
analyzer. After three baseline measurements, either vehicle or TUG-891 (10 lM) was injected into the wells.
E WT and GPR120 KO brown adipocytes were incubated with the calcium-sensitive dye Fluo-4-AM for 1 h at RT, followed by live cell imaging with a confocal laser
scanning microscope (LSM 510, Zeiss) and stimulation with TUG-891 (10 lM) with or without the presence of AH7614 (100 lM). F1/F0 represents peak fluorescence
divided by baseline fluorescence.
F Representative images of a brown adipocyte stained with MitoTracker Green FM (125 nM) and MitoTracker Red CMXRos (250 nM) before and after stimulation
with TUG-891 (10 lM) for 10 min. Fluorescence intensity of MTR/MTG was determined in TUG-891-treated cells and controls (n = 8–9) at baseline and after
10 min of fluorescence imaging, and plotted relative to baseline.
G Representative images of a brown adipocyte stained with MitoTracker Green FM at baseline (0 min) and 2, 4, and 8 min after TUG-891 stimulation. MitoTracker-
stained live cells were imaged using a confocal laser scanning microscope (Leica TCS SP8, Leica Microsystems).
Data information: Data represent means  SEM. **P < 0.01, ***P < 0.001 compared to the vehicle group, #P < 0.05 compared to the TUG-891 control group (or baseline
in Fig 7F), according to the two-tailed unpaired Student’s t-test. The exact P-value for each significant difference can be found in Appendix Table S5.
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Quesada-Lo´pez et al (2016). They showed that the GPR120 agonist
GW9508 upregulated thermogenic genes in BAT and increased O2
consumption in mice, without changes in body weight and food
intake. However, GW9508 also increased O2 consumption and UCP1
levels in GPR120 KO animals. Potentially, these effects of GW9508
are mediated through GPR40 (Ou et al, 2013), as GW9508 activates
both GPR40 and GPR120 and is approximately 100-fold more selec-
tive for GPR40 than GPR120 (Briscoe et al, 2006). GPR40 is involved
in insulin secretion and glucose metabolism (Itoh et al, 2003; El-
Azzouny et al, 2014), and GPR40 KO mice develop obesity, glucose
intolerance, and insulin resistance (Kebede et al, 2008). Also, acti-
vation of GPR40 has recently been shown to reduce food intake and
body weight in mice (Gorski et al, 2017). In our study, food intake
was reduced in both wild-type and GPR120 KO mice treated with
TUG-891. Therefore, this effect might be mediated through GPR40
instead of GPR120. However, effects of TUG-891 on body weight, fat
mass, and fat oxidation were reduced or absent in GPR120 KO mice,
confirming that these beneficial metabolic effects of TUG-891 were
predominately mediated through GPR120.
We next verified whether the BAT-activating effects of TUG-891
in vivo were a consequence of a direct effect of TUG-891 on brown
adipocytes. In line with the acute effect of TUG-891 on the RER and
fat oxidation in vivo, TUG-891 acutely increased O2 consumption by
brown adipocytes in vitro. This indicates that the effects of TUG-891
in vivo could all have been mediated by direct BAT activation.
However, we cannot exclude involvement of other tissues, as
GPR120 is not exclusively expressed on brown adipocytes. For
example, GPR120 is expressed in the hypothalamus and central
agonism of GPR120 has been shown to affect energy metabolism
(Auguste et al, 2016; Dragano et al, 2017). However, as carboxylic
acids similar to TUG-891 have difficulty penetrating the blood–brain
barrier, this is not very likely (Pajouhesh & Lenz, 2005). Also, con-
flicting reports exist on whether GPR120 plays a role in muscle
physiology and metabolism (Oh et al, 2010; Kim et al, 2015). In our
study, expression of Gadd45a, Murf1, and Myog in skeletal muscle
tissue was mildly affected by TUG-891 treatment. Whether this is an
off-target effect or GPR120-mediated effect, which could affect
muscle function, remains to be investigated. Future experiments
with tissue-specific GPR120 KO mice would be valuable to assess
tissue specificity of TUG-891. In addition, it would be interesting to
repeat our in vivo experiments at thermoneutrality, to substantiate
the link between BAT activation and the observed phenotype.
Using a GPR120 antagonist, we discovered that the TUG-891-
induced increase in O2 consumption in brown adipocytes is only
Figure 8. Proposed mechanism by which the GPR120 agonist TUG-891 activates BAT.
TUG-891 selectively agonizes the Gaq-coupled GPR120, which activates phospholipase C (PLC). Upon activation, PLC cleaves phospholipid phosphatidylinositol 4,5-
bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol trisphosphate (IP3). IP3 triggers the opening of Ca2+ channels in the membrane of the endoplasmic reticulum,
thereby increasing intracellular Ca2+ concentrations. Increased Ca2+ leads to depolarization of the mitochondria, and subsequently induction of mitochondrial fission which
increases respiration. In addition, TUG-891 directly activates UCP1, further stimulating uncoupled respiration and lipid combustion. As a consequence, the activated brown
adipocytes take up fatty acids (FA) from triglyceride (TG)-rich lipoproteins from the circulation, which eventually reduces fat mass.
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partly mediated by GPR120. The GPR120-independent effect of
TUG-891 could be due to direct activation of mitochondrial UCP1.
TUG-891 relieves the natural inhibition of UCP1 by GDP (Matthias
et al, 2000), similar to oleate and other LCFAs (Shabalina et al,
2004; Fedorenko et al, 2012), thereby leading to increased UCP1
activity and uncoupled mitochondrial respiration. This could
explain the moderately decreased fat mass and increased FA uptake
by BAT in TUG-891-treated GPR120 KO mice. However, as most
metabolic effects of TUG-891 were largely attenuated or abolished
in GPR120 KO mice, BAT activation by TUG-891 in vivo is mainly
dependent on GPR120 signaling.
To investigate through which mechanism GPR120 signaling
could increase brown adipocyte activity, several Gaq-coupled
signaling pathways were studied: the PI3K/AKT pathway, MAPK/
ERK pathway, and signaling through Ca2+. Of these, only the
intracellular Ca2+ availability was proven to be essential for
GPR120-mediated activation of brown adipocytes. A recent study
showed that Ca2+ could increase respiration in brown adipocytes by
decreasing the mitochondrial membrane potential (MMP) (Hou
et al, 2017). Evidently, the b receptor agonist isoprenaline induces
Ca2+ release from the endoplasmic reticulum of brown adipocytes
resulting in mitochondrial depolarization and fission (Hou et al,
2017), the latter being a process required for NA-induced uncoupled
respiration (Wikstrom et al, 2014). Therefore, we studied whether
this Ca2+-mediated pathway of mitochondrial depolarization and
fission could also underlie GPR120-mediated activation of brown
adipocytes. Mitochondria were co-stained with the MMP-sensitive
MitoTracker CMXRos (MTR) and the MMP-insensitive MitoTracker
Green (MTG) (Pendergrass et al, 2004), and the relative ratio of
MTR/MTG was used as a measure for mitochondrial depolarization
(as seen in (Wikstrom et al, 2014) in which TMRE was used instead
of MTR. TUG-891 stimulation resulted in a reduction in the MTR/
MTG ratio, indicative of mitochondrial depolarization. Also, TUG-
891 increased mitochondrial fragmentation, presumably secondary
to Ca2+-induced mitochondrial depolarization. These results suggest
that GPR120 signaling could increase metabolic activity of brown
adipocytes by stimulation of mitochondrial fission in a Ca2+-
dependent manner.
We conclude that TUG-891, an agonist of the free FA receptor
GPR120, directly stimulates BAT activity via both GPR120-
dependent and GPR120-independent mechanisms (Fig 8). As a
consequence, lipid uptake and oxidation by BAT increases, eventu-
ally reducing body weight and fat mass. Since impaired GPR120
signaling predisposes to obesity in humans (Ichimura et al, 2012),
obese individuals could benefit from GPR120 activation. Although
further studies are needed to investigate the safety of TUG-891 and
the potential of GPR120 agonists to activate BAT in humans, we
thus anticipate that GPR120 agonism is a promising therapeutic
strategy to increase BAT activity, thereby increasing fat oxidation
and reducing obesity.
Materials and Methods
Animals
To assess effects of TUG-891 on energy metabolism, 8- to 10-
week-old male C57Bl/6J mice (Charles River Laboratories) were
randomized to receive an intraperitoneal injection with either
TUG-891 (35 mg/kg) or 10% dimethyl sulfoxide (DMSO) vehicle
dissolved in PBS once daily for 2.5 weeks. TUG-891 was synthe-
sized as previously described (Shimpukade et al, 2012) and was of
> 99.5% purity, as assessed by HPLC and NMR. Mice were injected
2 h before initiation of the dark phase. To evaluate the specificity of
TUG-891 for GPR120, this experiment was also performed in 10- to
14-week-old male GPR120 knockout (KO) mice and wild-type (WT)
littermates on a C57Bl/6J background for a total period of 2 weeks.
All mice were housed in conventional cages with a 12-h light/dark
cycle and had ad libitum access to chow diet and water. Mouse
experiments were performed in accordance with the Institute for
Laboratory Animal Research Guide for the Care and Use of Labora-
tory Animals after having received approval from the University
Ethical Review Board (Leiden University Medical Center, Leiden,
The Netherlands).
To evaluate Gpr120 gene expression in various tissues, 12-week-
old FVB/N female mice were sacrificed by cervical dislocation and
organs were collected. Mice were housed in conventional cages with
a 12-h light/dark cycle and had ad libitum access to chow diet and
water, and experiments were carried out in accordance with UK
Home Office regulations.
For experiments in which mitochondrial respiration was
measured, mitochondria were isolated from 8- to 10-week-old male
UCP1 KO mice (progeny of those described in Enerback et al, 1997)
backcrossed to C57Bl/6J mice and wild-type C57Bl/6J mice. Mice
were housed in conventional cages with a 12-h light/dark cycle and
had ad libitum access to chow diet and water, and experiments were
carried out in accordance with the Animal Ethics Committee of the
North Stockholm region in Sweden.
Food intake, body weight, and body composition measurements
At the indicated time points, food intake and body weight of mice
were measured with a scale, and lean and fat mass with an
EchoMRI-100-analyzer.
Indirect calorimetry
Indirect calorimetry was performed in fully automated metabolic
cages (LabMaster System, TSE Systems) during the first week of
treatment. After 3 days of acclimatization, O2 consumption (VO2),
CO2 production (VCO2), and caloric intake were measured for 5
consecutive days. Total EE was estimated from the VO2 and rest-
ing energy requirement. Carbohydrate oxidation was calculated
using the formula ((4.585*VCO2)  (3.226*VO2))*4, in which the
4 represents the conversion from mass per time unit to kcal per
time unit (Peronnet & Massicotte, 1991). Similarly, fat oxidation
was calculated using the formula ((1.695*VO2)  (1.701*VCO2))
*9. Physical activity was measured with infrared sensor frames.
Tissue histology and immunohistochemistry
Formalin-fixed interscapular BAT (iBAT), subcutaneousWAT (sWAT),
and gonadal WAT (gWAT) were dehydrated in 70% EtOH, embedded
in paraffin, and cut into 5-lm sections. Sections were stained with
hematoxylin and eosin (H&E) using standard protocols. UCP1 staining
was performed as previously described (Berbee et al, 2015). In short,
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sections were treated with 3% H2O2 for 30 min and boiled in citrate
buffer (10 mM, pH 6) for 10 min. Slides were blocked with 1.3%
normal goat serum, incubated overnight at 4°C with rabbit monoclonal
anti-UCP1 antibody (1:400, Abcam) followed by 1-h incubation with
biotinylated goat a-rabbit secondary antibody (Vector Labs). Immuno-
staining was amplified using Vector Laboratories Elite ABC kit (Vector
Labs) and visualized with Nova Red (Vector Labs). Counterstaining
was performed with hematoxylin. All sections were digitalized with
Philips Digital Pathology Solutions (PHILIPS Electronics) for morpho-
logical measurement. White adipocyte size, iBAT lipid droplet content,
and UCP1 expression (relative UCP1 staining per area) were quantified
using ImageJ software (Version 1.50).
Plasma triglycerides
After 6 h of food withdrawal, blood was collected from the tail vein
in paraoxon-coated capillaries, and plasma levels of TG were deter-
mined using an enzymatic kit (Roche Diagnostics)
RNA isolation, cDNA synthesis, and qRT–PCR
Tissues or cells were dissolved in TRIzol RNA isolation reagent
(Thermo Fisher) following the manufacturer’s protocol. The RNA
concentration was determined with a NanoDrop spectrophotometer
(Thermo Fisher). For removal of genomic DNA, samples were
treated with DNase I (Sigma), after which total RNA was reverse-
transcribed with M-MLV Reverse Transcriptase (Sigma). The qRT–
PCR was performed with a SYBR Green kit (Sigma) on a 7500 Fast
RT–PCR System (Applied Biosystems). Primer sequences are listed
in Appendix Table S1. mRNA expression of genes of interest was
normalized to mRNA expression of the housekeeping genes L19,
b-Actin, and/or b2-microglobulin.
Protein isolation and Western blot analysis
Cells were stimulated with TUG-891 (10 lM) for 5 min to assess
phosphorylation of ERK and AKT after which they were lysed in ice-
cold RIPA buffer (50 mM Tris–HCL pH 8, 1 mM EDTA, 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing
protease and phosphatase inhibitor cocktails (Roche). Homogenates
were centrifuged, and protein content of the supernatant was deter-
mined using a Coomassie Protein Assay Kit (Thermo Fisher). After
heating the samples (5 min, 95°C), 20 lg of protein was separated
by 12% SDS–PAGE, followed by transfer to a PVDF membrane
using the Trans-Blot Turbo Transfer System (Bio-Rad). Membranes
were blocked with 5% milk, incubated overnight at 4°C with
protein-specific primary antibody followed by incubation for 1 h
with horseradish peroxidase (HRP)-conjugated secondary antibodies
(Goat anti-Rabbit HRP, Dako P0448 at 1:2,000 or Promega W4018 at
1:1,000). Primary antibodies used were rabbit anti-pHSL563 (Cell
Signaling #4139 at 1:1,000), rabbit anti-UCP1 (Sigma U6382 at
1:4,000), rabbit anti-tubulin (Cell Signaling #2148 at 1:1,000), rabbit
anti-pPKA substrate (Cell Signalling #9612 at 1:1,000), rabbit anti-
pERK 1/2 (Cell Signaling #9101 at 1:500), rabbit anti-ERK 1/2 (Cell
Signaling #4695 at 1:5,000), rabbit anti-pAKT (Ser 473) (Cell Signal-
ing #9271 at 1:1,000), rabbit anti-AKT (Cell Signaling #9272 at
1:1,000), and mouse anti-b-Actin HRP (Santa Cruz sc-47778 at
1:5,000). Bands were visualized using Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare) and quantified
using ImageJ software (Version 1.50).
Clearance of radiolabeled lipoprotein-like emulsion particles
and glucose
Glycerol tri[3H]oleate ([3H]TO)-labeled lipoprotein-like TG-rich
emulsion particles (80 nm) were prepared and characterized as
described previously (Rensen et al, 1995), and [14C]deoxyglucose
([14C]DG) was added (ratio 3H:14C = 4:1). Mice were fasted for 6 h
and injected with 200 ll of emulsion particles (1 mg TG per mouse)
via the tail vein, 1 h after onset of the dark phase (i.e., 3 h after
injection of TUG891 or vehicle). After 15 min, mice were sacrificed
by cervical dislocation and perfused with ice-cold PBS through
the heart. Thereafter, organs were harvested and weighed, and
dissolved overnight at 56°C in Tissue Solubilizer (Amersham Bio-
sciences). The uptake of [3H]TO- and [14C]DG-derived radioactivity
was quantified and expressed per gram of wet tissue weight or per
organ for organs that could be taken out quantitatively.
Microarray experiments
iBAT from GPR120 KO mice (Godinot et al, 2013) and WT litter-
mates with similar body weights were analyzed. Global mRNA
expression was measured using Illumina bead chip. Whole-genome
expression was profiled using MouseWG-6 v2.0 Expression Bead-
Chips (Kuhn et al, 2004). The summary-level data were processed
using the R packages lumi 2.10.0, lumiMouseAll.db 1.18.0, and
lumiMouseIDMapping 1.10.0 using nuID annotations (Du et al,
2007). The data were normalized using quantile normalization. Dif-
ferentially expressed genes (DEGs) between WT and KO samples
were detected based on a moderated t-test using limma on the
normalized data, removing unexpressed genes. The normalized
expression data were filtered using the absolute value of logFC < 0.5
and adjusted P-value < 0.05, converted into z-scores, and heatmap.2
was used to visualize the data. DEGs with P < 0.05 were submitted
to DAVID (Database for Annotation, Visualization and Integrated
Discovery) for functional classification by using RefSeq mRNA acces-
sion numbers. Functional clusters were considered significant for
FDR (false discovery rate) < 0.01 (da Huang et al, 2009).
Cell culture
Previously described immortalized cell lines of primary cultures of
BAT and sWAT were used for experiments (Rosell et al, 2014).
Immortalized GPR120 KO brown adipocytes were generated in the
same way as these primary culture cell lines, that is, by retroviral-
mediated transformation of SV40 large T-antigen. Brown and white
preadipocytes were cultured in DMEM/F12 (Sigma) supplemented
with 10% fetal bovine serum (FBS) and penicillin–streptomycin
(Sigma). Preadipocytes were differentiated with induction medium
for 2 days and with maintenance medium for 6 days. The constitu-
ents of this medium and their concentrations are listed in
Appendix Table S2. To assess effects of browning of white adipo-
cytes on gene expression, the induction medium was modulated to
contain 5 lM rosiglitazone, after which the cells received 1 lM of
rosiglitazone during the first 4 days of maintenance. Adipocytes
were used for experiments on day 7–9 of differentiation.
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Oil Red O staining
Differentiated immortalized brown adipocytes were fixed with 4%
paraformaldehyde (15 min, RT) and rinsed with 60% isopropanol.
Cells were stained with 0.15% Oil Red O (Sigma) in 60% isopro-
panol (30 min, RT), after which they were washed with 60% isopro-
panol. Images were taken with a phase-contrast microscope (Leica).
Cellular oxygen consumption measurements
Seahorse Bioscience XF24 extracellular flux analyzer (Seahorse
Bioscience) was used to measure the OCR in differentiated brown
adipocytes. On day 7 of differentiation, cells were trypsinized and
seeded in a 24-well Seahorse Bioscience assay plate. The next day,
cells were pretreated with BAPTA-AM (25 lM; Thermo Fisher),
U0126 (10 lM; Promega), or AKT 1/2 kinase inhibitor (10 lM;
A6730, Sigma) for 30 min (37°C, without CO2) before starting
Seahorse analysis. Vehicle (DMSO), TUG-891, and/or CL316243
(CL) were preloaded in the reagent delivery chambers and pneumat-
ically injected into the wells after three baseline measurements (to a
final concentration of 10 lM TUG-891 or CL). Cellular O2 consump-
tion was measured in real time every 7 min.
Isolation of mitochondria
Brown fat mitochondria were prepared as previously described
(Cannon & Nedergaard, 2008; Shabalina et al, 2010). Routinely, on
each experimental day, three mice were anaesthetized for 1–2 min
by a mixture of 79% CO2 and 21% O2, and decapitated. The inter-
scapular, axillary, and cervical BAT depots were dissected out,
cleaned from WAT, and pooled in ice-cold isolation buffer, SHE
consisting of 250 mM sucrose, 10 mM HEPES (pH 7.2), 0.1 mM
EGTA, and 2% (w/v) FA-free BSA (10775835001 Roche Diagnos-
tics GmbH). Throughout the isolation process, the tissue was kept
at 0–4°C. Tissue was minced with scissors, homogenized in SHE
buffer with a motorized Potter-Elvehjem Teflon pestle, filtered
through cotton gauze, and centrifuged at 8,800 g for 10 min. The
supernatant with the floating fat layer was discarded. The resus-
pended homogenate was centrifuged at 800 g for 10 min, and the
resulting supernatant was centrifuged at 8,800 g for 10 min. The
resulting mitochondrial pellet was resuspended in 100 mM KCl,
20 mM K+-Tes (pH 7.2), and centrifuged again at 8,800 g for
10 min. The final mitochondrial pellets were resuspended by hand
homogenization in a small glass homogenizer in the same medium
to yield a concentration of roughly 25–35 mg/ml mitochondrial
protein. The concentration of mitochondrial protein was measured
using fluorescamine (Fluram, 47614 Sigma-Aldrich; Udenfriend
et al, 1972) with BSA as a standard. Mitochondria were stored on
ice, and aliquots were removed as required during functional
analyses.
Mitochondrial oxygen consumption measurements
For oxygen consumption measurements, isolated brown fat mito-
chondria (0.25 mg protein) were added to 2.0 ml of a continuously
stirred incubation medium consisting of 100 mM KCl, 20 mM K+-
Tes (pH 7.2), 2 mM MgCl2, 1 mM EDTA, 4 mM KPi, 3 mM malate,
5 mM pyruvate (Sigma-Aldrich), and 0.1% FA-free BSA. Oxygen
consumption rates were monitored using an O2k-MultiSensor
System (Oroboros Instruments) in a sealed incubation chamber at
37°C. During prolonged recording, re-oxygenation of respiratory
buffer was performed by unsealing of chamber. Basal respiration
was measured in the presence of 1–3 mM GDP (dissolved in 20 mM
Tes (final pH 7.2), G7127 Sigma-Aldrich). Maximal oxygen
consumption rates (respiratory capacity) were obtained by addition
of the ionophoric uncoupling agent FCCP (C2920, Sigma-Aldrich) at
a final concentration of 1.0–1.4 lM. TUG-891 was dissolved in
DMSO at a stock concentration of 100 mM or 20 mM and used for
titration by adding 1–2 ll to 2-ml chamber.
Calcium mobilization assays
Differentiated cells were incubated for 1 h at RT with the calcium-
sensitive dye Fluo-4-AM (Invitrogen) in Krebs–Ringer bicarbonate
buffer (Sigma). Hereafter, the cells were washed twice with buffer,
followed by live cell imaging with a confocal laser scanning micro-
scope (LSM 510, Zeiss) and stimulation with TUG-891 (10 lM),
with or without preincubation with the GPR120 antagonist AH7614
for 5 min (100 lM; Tocris) or the Gaq inhibitor YM-254890 for
30 min (0.1 lM, Alpha Laboratories).
MitoTracker experiments
Differentiated adipocytes were incubated for 30 min with Mito-
Tracker Green FM (125 nM; Thermo Fisher) and MitoTracker Red
CMXRos (250 nM; Thermo Fisher) in DMEM/F12 (Sigma) without
FBS. Hereafter, the medium was changed and live cells were imaged
using a confocal LSM (Leica TCS SP8, Leica Microsystems). Adipo-
cytes were stimulated with TUG-891 (10 lM), followed by live cell
imaging for 10 min to monitor mitochondrial morphology. Control
cells were monitored to correct for potential photobleaching, and
corrected total cell fluorescence (CTSF, integrated density  (area
of selected cell × mean fluorescence of background)) of 8–9 cells
per condition was quantified using ImageJ.
cAMP measurements
Measurement of whole cell cAMP was carried out with the cAMP
dynamic 2 kit (Cisbio Bioassays, 62AM4PEC) as per manufacturer’s
instructions. Cells were pretreated with phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine (IBMX, 0.5 mM, 5 min) prior to ligand
treatment and lysed in 0.1 M HCl/0.1% Triton X-100. All cAMP
concentrations were corrected for protein levels.
Statistical analysis
All data are expressed as mean  SEM. Statistical analysis was
performed using two-tailed unpaired Student’s t-test or ANOVA with
Tukey’s post hoc test using SPSS Statistics (Version 23.0). Dif-
ferences between groups were considered statistically significant at
P < 0.05.
Data availability
The microarray data from this publication have been deposited to
NCBI’s Gene Expression Omnibus (Edgar et al, 2002) and assigned
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the GEO Series accession number GSE97145 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE97145).
Expanded View for this article is available online.
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The GPR120 agonist TUG-891 promotes metabolic health by stimulating 
mitochondrial respiration in brown fat 
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Appendix Table S1. Primer sequences for qRT-PCR. 
 
Gene Primer sequence Product length (bp) 
Aacs Forward 
Reverse 
5’- CTGTCAGTGCTGGAGGAGAA -3’ 
5’- TGGCCCATGAAACAGGAGAT -3’ 
191 
Acaa2 Forward 
Reverse 
5’- AGAAGGCCCTGGATCTTGAC -3’ 
5’- CTCCAATGCAAGCTGATCCC -3’ 
162 
Acc1 Forward 
Reverse 
5’- TGTCCACCCAAGCATTTCTTC -3’ 
5’- CATCCAACACCAGTTCAGTATACGT -3’ 
75 
Acc2 Forward 
Reverse 
5’- ACTTTGACCTGACCGCTGTG -3’ 
5’- CTGAGTGCCGGATAATGGC -3’ 
129 
Acsl1 Forward 
Reverse 
5’- CAGAACCCGAAGATCTTGCG -3’ 
5’- CGGTCTCAAACATATGGGCG -3’ 
192 
Adcy4 Forward 
Reverse 
5’- CCTCATTGCCCGCCTTTATC -3’ 
5’- GTCTCAGTCTCCTCTCGCTC -3’ 
195 
Adhfe1 Forward 
Reverse 
5’- CCAGCTCCCTCCTGTACAAA -3’ 
5’- CCCACAGCAACATAGGCATC -3’ 
159 
Adrb3 Forward 
Reverse 
5’- ATCGTGTCCGCTGCCGT -3’ 
5’- ATCTGCCCCTACACGCCAC -3’ 
63 
Aldh2 Forward 
Reverse 
5’- GAGCAGAGCCATGTCATGTG -3’ 
5’- TGTCACACATCCAGGCATCT -3’ 
218 
aP2 Forward 
Reverse 
5’- ACACCGAGATTTCCTTCAAACTG -3’ 
5’- CCATCTAGGGTTATGATGCTCTTCA -3’ 
88 
Apoc1 Forward 
Reverse 
5’- GAGGGCGGTGGTGAATACTA -3’ 
5’- ATGCTCTCCAATGTTCCGGA -3’ 
183 
Atgl Forward 
Reverse 
5’- GCCAATGTCTGCAGCACATT -3’ 
5’- CATAGCGCACCCCTTGGA -3’ 
73 
Ccl2 (Mcp1) Forward 
Reverse 
5’- CAGGTCCCTGTCATGCTTCT -3’ 
5’- GAGTGGGGCGTTAACTGCAT -3’ 
93 
Ccl5 (Rantes) Forward 
Reverse 
5’- GCAAGTGCTCCAATCTTGCA -3’ 
5’- CTTCTCTGGGTTGGCACACA -3’ 
71 
Ccna Forward 
Reverse 
5’- CTGAAGGCCGGGAACGTG -3’ 
5’- CCTTAAGAGGAGCAACCCGT -3’ 
73 
Ccnb Forward 
Reverse 
5’- AAATTGCAGCTGGGGCTTTC -3’ 
5’- TGCAGAGTTGGTGTCCATTCA -3’ 
70 
Cd36 Forward 
Reverse 
5’- GATGTGGAACCCATAACTGGA -3’ 
5’- GGCTTGACCAATATGTTGACC -3’ 
71 
Cd68 Forward 
Reverse 
5’- CCAATTCAGGGTGGAAGAAA -3’ 
5’- GAGAGAGACAGGTGGGGATG -3’ 
104 
Cidea Forward 
Reverse 
5’- CACGCATTTCATGATCTTGGA -3’ 
5’- GTTGCTTGCAGACTGGGACAT -3’ 
74 
Ctgf Forward 
Reverse 
5’- AGCTGGGAGAACTGTGTACG -3’ 
5’- GCCAAATGTGTCTTCCAGTC -3’ 
380 
Dgat2 Forward 
Reverse 
5’- TCGCGAGTACCTGATGTCTG -3’ 
5’- CTTCAGGGTGACTGCGTTCT -3’ 
160 
Fasn Forward 
Reverse 
5’- TGCGGAAACTTCAGGAAATGT -3’ 
5’- AGAGACGTGTCACTCCTGGACTT -3’ 
82 
Gadd45a Forward 
Reverse 
5’- GCTGCCAAGCTGCTCAAC -3’ 
5’- TCGTCGTCTTCGTCAGCA -3’ 
71 
G0s2 Forward 
Reverse 
5’- AGTGCTGCCTCTCTTCCCAC -3’ 
5’- TTTCCATCTGAGCTCTGGGC -3’ 
65 
Glut1 Forward 
Reverse 
5’- GACGGGCCGCCTCATGTTGG -3’ 
5’- GCTCTCCGTAGCGGTGGTTCC -3’ 
140 
Glut4 Forward  
Reverse 
5’- CTATTCAACCAGCATCTTCGAG -3’ 
5’- CTACTAAGAGCACCGAGACC -3’ 
110 
Gpr120 Forward 
Reverse 
5’- CCCCTCTGCATCTTGTTCC -3’ 
5’- GATTTCTCCTATGCGGTTGG -3’ 
102 
Gys2 Forward 
Reverse 
5’- ATCCTTTCTCGTGCCAGGAA -3’ 
5’- GCGGTGGTATATCTGCCTCT -3’ 
159 
Hsl Forward 
Reverse 
5’- CGAGACAGGCCTCAGTGTGA -3’ 
5’- TCTGGGTCTATGGCGAATCG -3’ 
66 
Il6 Forward 
Reverse 
5’- CTCTGGGAAATCGTGGAAAT -3’ 
5’- CCAGTTTGGTAGCATCCATC -3’ 
134 
Insr Forward 
Reverse 
5’- CTACAGTGTTCGAGTCCGGG -3’ 
5’- TGGCAATATTTGATGGGACATCT -3’ 
107 
L19 Forward 
Reverse 
5’- GGAAAAAGAAGGTCTGGTTGGA -3’ 
5’- TGATCTGCTGACGGGAGTTG -3’ 
72 
Lgals3 Forward 
Reverse 
5’- CAACCATCGGATGAAGAACC -3’ 
5’- TTCCCACTCCTAAGGCACAC -3’ 
141 
Lpl Forward 
Reverse 
5’- CAAGACCTTCGTGGTGATCCA -3’ 
5’- GTACAGGGCGGCCACAAGT -3’ 
82 
Mki67 Forward 
Reverse 
5’- ACAGGCTCCGTACTTTCCAA -3’ 
5’- ACTGGATAGCACTTTTTCTCCCAA -3’ 
120 
Mlxipl Forward 
Reverse 
5’- CCCTCAGACACCCACATCTT -3’ 
5’- TCAGAAAGGGGTTGGGATCC -3’ 
209 
Murf1 Forward 
Reverse 
5’- TGTGCAAGGAACACGAAGAC -3’ 
5’- CCAGCATGGAGATGCAGTTA -3’ 
171 
Myog Forward 
Reverse 
5’- CCCAACCCAGGAGATCATTT -3’ 
5’- GTCTGGGAAGGCAACAGACA -3’ 
117 
Paqr9 Forward 
Reverse 
5’- GGTTTGCGTGGAGTTTCTGT -3’ 
5’- TGTTTCACCTCCCATCTCCC -3’ 
172 
Pgc1α Forward 
Reverse 
5’- GATGGCACGCAGCCCTAT -3’ 
5’- CTCGACACGGAGAGTTAAAGGAA -3’ 
70 
Pnpla3 Forward 
Reverse 
5’- ACCTGAGAGCCTGCAATCTT -3’ 
5’- AACAGAACCCTTCCCAGAGG -3’ 
217 
Pgc1α Forward 
Reverse 
5’- GATGGCACGCAGCCCTAT -3’ 
5’- CTCGACACGGAGAGTTAAAGGAA -3’ 
70 
Pparα Forward 
Reverse 
5’- ATGCCAGTACTGCCGTTTTC -3’ 
5’- GGCCTTGACCTTGTTCATGT -3’ 
220 
Pparγ Forward 
Reverse 
5’- TTGTAGAGTGCCAGGTGCTG -3’ 
5’- CCTCCATAGCTCAGGTGGAA -3’ 
151 
Scd1 Forward 
Reverse 
5’- CCCCTGCGGATCTTCCTTAT -3’ 
5’- AGGGTCGGCGTGTGTTTCT -3’ 
114 
Scd2 Forward 
Reverse 
5’- AGCGGGCTGCAGAAACTTAG -3’ 
5’- GGCTGAGTAAGCGCCAGAGAT -3’ 
148 
Sncg Forward 
Reverse 
5’- CAAGGAAGGTGTTGTGGGTG -3’ 
5’- CTTGTTGGCCACTGTGTTGA -3’ 
208 
Srebp1c Forward 
Reverse 
5’- ATGCCATGGGCAAGTACACA -3’ 
5’- ATAGCATCTCCTGCGCACTC -3’ 
91 
Tnfα Forward 
Reverse 
5’- ATGAGAAGTTCCCAAATGGC -3’ 
5’- CTCCACTTGGTGGTTTGCTA -3’ 
125 
Ucp1 Forward 
Reverse  
5’- TACCCAAGCGTACCAAGCTG -3’ 
5’- ACCCGAGTCGCAGAAAAGAA -3’ 
97 
Vegf Forward 
Reverse 
5’- CATCTTCAAGCCGTCCTGTGT -3’ 
5’- CTCCAGGGCTTCATCGTTACA -3’ 
67 
Vldlr Forward 
Reverse 
5’- GCCCTGAACAGTGCCATATG -3’ 
5’- CATCACTGCCATCGTCACAG -3’ 
243 
β-Actin Forward 
Reverse 
5’- GCAGGAGTACGATGAGTCCG -3’ 
5’- ACGCAGCTCAGTAACAGT -3’ 
74 
β-2 
microglobulin 
Forward 
Reverse 
5’- TGACCGGCTTGTATGCTATC -3’ 
5’- CAGTGTGAGCCAGGATATAG -3’ 
222 
 
 
Appendix Table S2. Culture medium compounds and their concentrations. 
 
Compound ImBA 
Induction 
ImBA 
Maintenance 
ImWA 
Induction 
ImWA 
Maintenance 
Thyroid hormone T3 1 nM 1 nM 0.1 nM 0.1 nM 
Insulin 1 μg/ml 1 μg/ml 5 μg/ml 5 μg/ml 
Biotin 16 μM 16 μM 16 μM 16 μM 
Pantothenate 1.8 μM 1.8 μM 1.8 μM 1.8 μM 
Ascorbic acid 100 μM 100 μM 100 μM 100 μM 
IBMX 0.5 mM - 0.5 mM - 
Dexamethasone 250 nM - 250 nM - 
Indomethacin 125 μM - - - 
Cortisol - - 100 nM - 
Rosiglitazone - - 1 μM - 
ImBA: immortalized brown adipocytes, ImWA: immortalized white adipocytes. 
 
Appendix Table S3. Genes upregulated or downregulated in the absence of GPR120. 
 
Table S3A. Genes upregulated in BAT from GPR120 KO versus WT mice. 
Gene Symbol Gene Name FC Adj P 
Value 
Sncg synuclein, gamma 1.99 0.037 
Xlr4a X-linked lymphocyte-regulated 4A 1.86 0.047 
Npm3-ps1 nucleoplasmin 3, pseudogene 1 1.75 0.039 
Cd52 CD52 antigen 1.71 0.014 
Rarres2 retinoic acid receptor responder (tazarotene induced) 2 1.71 0.021 
Hist1h2ap histone cluster 1, H2ap 1.68 0.011 
Wdfy1 WD repeat and FYVE domain containing 1 1.67 0.021 
Cxcl9 chemokine (C-X-C motif) ligand 9 1.65 0.011 
Hist1h2ad histone cluster 1, H2ad 1.62 0.011 
Ccl11 chemokine (C-C motif) ligand 11 1.62 0.023 
Npm3 nucleoplasmin 3 1.52 0.040 
Hebp1 heme binding protein 1 1.52 0.013 
Coro1a coronin, actin binding protein 1A 1.52 0.008 
Hn1 hematological and neurological expressed sequence 1 1.50 0.023 
Rps12-ps24 Ribosomal protein S12, pseudogene 24 1.49 0.028 
Cd74 
CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-associated) 
1.48 0.045 
Hist1h2ai histone cluster 1, H2ai 1.48 0.022 
Sae1 SUMO1 activating enzyme subunit 1 1.48 0.009 
Gm11425 predicted gene 11425 1.46 0.034 
Psmb9 
proteasome (prosome, macropain) subunit, beta type 9 
(large multifunctional peptidase 2) 
1.45 0.005 
Slamf9 SLAM family member 9 1.45 0.031 
Pigp phosphatidylinositol glycan anchor biosynthesis, class P 1.45 0.034 
Maged2 melanoma antigen, family D, 2 1.45 0.011 
H2-Eb1 histocompatibility 2, class II antigen E beta 1.44 0.034 
Hist1h2af histone cluster 1, H2af 1.44 0.027 
Dus4l dihydrouridine synthase 4-like (S. cerevisiae) 1.43 0.029 
Wbp5 WW domain binding protein 5 1.42 0.037 
Rpl12 ribosomal protein L12 1.41 0.031 
Rps5 ribosomal protein S5 1.41 0.046 
1110059E24Rik RIKEN cDNA 1110059E24 gene 1.41 0.003 
Mettl20 Methyltransferase like 20 1.41 0.025 
Anxa2 annexin A2 1.40 0.004 
Mgst3 microsomal glutathione S-transferase 3 1.39 0.026 
Nsmce1 non-SMC element 1 homolog (S. cerevisiae) 1.39 0.021 
Hist1h2an histone cluster 1, H2an 1.39 0.027 
Lsm5 
LSM5 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
1.38 0.034 
Mpeg1 macrophage expressed gene 1 1.38 0.025 
Ubxn6 UBX domain protein 6 1.38 0.023 
Rps12 ribosomal protein S12 1.38 0.026 
Evi2a ecotropic viral integration site 2a 1.38 0.034 
Arhgdib Rho, GDP dissociation inhibitor (GDI) beta 1.38 0.036 
Fbn1 fibrillin 1 1.37 0.049 
Rps26 ribosomal protein S26 1.37 0.034 
Rhoj ras homolog gene family, member J 1.37 0.015 
Ugt1a10 UDP glycosyltransferase 1 family, polypeptide A10 1.37 0.034 
Mgst3 microsomal glutathione S-transferase 3 1.36 0.009 
Tyrobp TYRO protein tyrosine kinase binding protein 1.36 0.031 
Ebpl emopamil binding protein-like 1.36 0.016 
Arpc3 actin related protein 2/3 complex, subunit 3 1.36 0.033 
Siva1 SIVA1, apoptosis-inducing factor 1.35 0.040 
 
Table S3B. Genes downregulated in BAT from GPR120 KO versus WT mice. 
Gene Symbol Gene Name FC Adj P 
Value 
O3far1 omega-3 fatty acid receptor 1 0.35 0.002 
Pnpla3 patatin-like phospholipase domain containing 3 0.38 0.016 
Hspa8 heat shock protein 8 0.41 0.001 
Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 0.43 0.038 
Adrbk2 adrenergic receptor kinase, beta 2 0.55 0.004 
Vegfa vascular endothelial growth factor A 0.55 0.003 
Apoc1 apolipoprotein C-I 0.55 0.004 
Mlxipl MLX interacting protein-like 0.56 0.007 
Hspd1 heat shock protein 1 (chaperonin) 0.56 0.017 
Luc7l3 LUC7-like 3 (S. cerevisiae) 0.58 0.015 
Per2 period homolog 2 (Drosophila) 0.60 0.011 
Atl2 atlastin GTPase 2 0.60 0.034 
Neat1 nuclear paraspeckle assembly transcript 1 (non-protein 0.61 0.050 
coding) 
Acsl1 acyl-CoA synthetase long-chain family member 1 0.61 0.041 
Ggnbp1 gametogenetin binding protein 1 0.61 0.011 
Slc4a4 solute carrier family 4 (anion exchanger), member 4 0.61 0.014 
Per2 period homolog 2 (Drosophila) 0.61 0.021 
Rnf44 ring finger protein 44 0.62 0.023 
Flcn folliculin 0.62 0.028 
Slc25a20 solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase), member 20 
0.62 0.025 
Atl2 atlastin GTPase 2 0.62 0.047 
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.62 0.011 
Srsf2 serine/arginine-rich splicing factor 2 0.63 0.016 
Slc38a2 solute carrier family 38, member 2 0.63 0.016 
Gys2 glycogen synthase 2 0.63 0.023 
Ddx17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 0.63 0.014 
Gm3308 predicted gene 3308 0.64 0.021 
Gm10621 predicted gene 10621 0.64 0.004 
Ccrn4l CCR4 carbon catabolite repression 4-like (S. cerevisiae) 0.64 0.024 
Actb actin, beta 0.64 0.021 
Aspg asparaginase homolog (S. cerevisiae) 0.64 0.021 
Clasrp CLK4-associating serine/arginine rich protein 0.64 0.013 
Pparγc1b peroxisome proliferative activated receptor, gamma, 
coactivator 1 beta 
0.64 0.029 
Apoc1 apolipoprotein C-I 0.65 0.034 
Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 0.65 0.017 
Adhfe1 alcohol dehydrogenase, iron containing, 1 0.65 0.028 
Klf9 Kruppel-like factor 9 0.65 0.029 
Aacs acetoacetyl-CoA synthetase 0.66 0.039 
Vegfα vascular endothelial growth factor A 0.66 0.003 
Srrm2 serine/arginine repetitive matrix 2 0.66 0.013 
2810403A07Ri
k 
RIKEN cDNA 2810403A07 gene 0.67 0.011 
Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B member 1 0.67 0.046 
Gtf3c2 general transcription factor IIIC, polypeptide 2, beta 0.67 0.011 
Lgals4 lectin, galactose binding, soluble 4 0.67 0.011 
Paqr9 progestin and adipoQ receptor family member IX 0.67 0.030 
Arap3 ArfGAP with RhoGAP domain, ankyrin repeat and PH 
domain 3 
0.68 0.030 
Slc1a5 solute carrier family 1 (neutral amino acid transporter), 
member 5 
0.68 0.001 
Fam126b family with sequence similarity 126, member B 0.68 0.022 
Slc1a5 solute carrier family 1 (neutral amino acid transporter), 
member 5 
0.68 0.003 
Gm2589 predicted gene 2589 0.68 0.012 
 
FC: fold change. 
 
 
 
Appendix Table S4. Functional annotation clustering of genes upregulated or downregulated 
in the absence of GPR120. 
 
Table S4A. DAVID (P=0.05), upregulated in GPR120 KO, 7 clusters with terms with FDR < 0.01. 
Annotation Cluster 1 Enrichment Score: 23.571326366746383  
Category Term FDR 
GOTERM_MF_FAT GO:0003735~structural constituent of ribosome 3.18E-27 
SP_PIR_KEYWORDS ribonucleoprotein 4.17E-26 
KEGG_PATHWAY mmu03010:Ribosome 6.46E-25 
GOTERM_CC_FAT GO:0005840~ribosome 3.05E-24 
SP_PIR_KEYWORDS ribosomal protein 3.34E-24 
GOTERM_CC_FAT GO:0030529~ribonucleoprotein complex 2.50E-23 
GOTERM_BP_FAT GO:0006412~translation 2.83E-21 
GOTERM_MF_FAT GO:0005198~structural molecule activity 1.14E-10 
GOTERM_CC_FAT GO:0033279~ribosomal subunit 3.05E-08 
   
Annotation Cluster 2 Enrichment Score: 5.009748166504468  
Category Term FDR 
GOTERM_CC_FAT GO:0043228~non-membrane-bounded organelle 5.14E-05 
GOTERM_CC_FAT GO:0043232~intracellular non-membrane-bounded organelle 5.14E-05 
   
Annotation Cluster 3 Enrichment Score: 3.6450159174973065  
Category Term FDR 
GOTERM_BP_FAT GO:0006396~RNA processing 3.92 E-03 
   
Annotation Cluster 6 Enrichment Score: 3.083826976916491  
Category Term FDR 
GOTERM_BP_FAT GO:0048002~antigen processing and presentation of peptide 
antigen 
1.72E-08 
GOTERM_BP_FAT GO:0002478~antigen processing and presentation of 
exogenous peptide antigen 
7.16E-06 
GOTERM_BP_FAT GO:0019882~antigen processing and presentation 9.29E-06 
GOTERM_BP_FAT GO:0019884~antigen processing and presentation of 
exogenous antigen 
1.00E-05 
GOTERM_BP_FAT GO:0002495~antigen processing and presentation of peptide 
antigen via MHC class II 
1.38E-05 
GOTERM_BP_FAT GO:0019886~antigen processing and presentation of 
exogenous peptide antigen via MHC class II 
1.38E-05 
GOTERM_BP_FAT GO:0002504~antigen processing and presentation of peptide 
or polysaccharide antigen via MHC class II 
1.33E-04 
   
Annotation Cluster 
15 
Enrichment Score: 2.4342394169368364  
Category Term FDR 
GOTERM_BP_FAT GO:0002443~leukocyte mediated immunity 1.62E-03 
GOTERM_BP_FAT GO:0002252~immune effector process 3.34E-03 
GOTERM_BP_FAT GO:0050778~positive regulation of immune response 4.05E-03 
GOTERM_BP_FAT GO:0048584~positive regulation of response to stimulus 6.99E-03 
   
Annotation Cluster 
17 
Enrichment Score: 2.306287251432978  
Category Term FDR 
GOTERM_BP_FAT GO:0050778~positive regulation of immune response 4.05E-03 
   
Annotation Cluster 
30 
Enrichment Score: 1.6629313948276978  
Category Term FDR 
KEGG_PATHWAY mmu05322:Systemic lupus erythematosus 6.07E-03 
 
Table S4B. DAVID (P=0.05), downregulated in GPR120 KO, 11 clusters with terms with FDR < 
0.01. 
Annotation Cluster 1 Enrichment Score: 18.04039228677734  
Category Term FDR 
GOTERM_CC_FAT GO:0005739~mitochondrion 1.54E-21 
SP_PIR_KEYWORDS mitochondrion 3.77E-18 
SP_PIR_KEYWORDS transit peptide 1.19E-15 
UP_SEQ_FEATURE transit peptide: Mitochondrion 4.19E-12 
GOTERM_CC_FAT GO:0044429~mitochondrial part 1.58E-10 
   
Annotation Cluster 2 Enrichment Score: 10.830871851860504  
Category Term FDR 
SP_PIR_KEYWORDS mitochondrion 3.77E-18 
GOTERM_CC_FAT GO:0031090~organelle membrane 1.56E-11 
GOTERM_CC_FAT GO:0044429~mitochondrial part 1.58E-10 
GOTERM_CC_FAT GO:0031966~mitochondrial membrane 9.36E-08 
GOTERM_CC_FAT GO:0019866~organelle inner membrane 1.02E-07 
GOTERM_CC_FAT GO:0031967~organelle envelope 6.85E-07 
GOTERM_CC_FAT GO:0031975~envelope 8.04E-07 
GOTERM_CC_FAT GO:0005740~mitochondrial envelope 1.09E-06 
GOTERM_CC_FAT GO:0005743~mitochondrial inner membrane 1.34E-06 
   
Annotation Cluster 3 Enrichment Score: 9.454393303217916  
Category Term FDR 
GOTERM_MF_FAT GO:0000166~nucleotide binding 1.68E-17 
GOTERM_MF_FAT GO:0017076~purine nucleotide binding 1.51E-08 
GOTERM_MF_FAT GO:0001882~nucleoside binding 4.75E-08 
GOTERM_MF_FAT GO:0001883~purine nucleoside binding 5.33E-08 
GOTERM_MF_FAT GO:0030554~adenyl nucleotide binding 9.68E-08 
GOTERM_MF_FAT GO:0032553~ribonucleotide binding 5.60E-06 
GOTERM_MF_FAT GO:0032555~purine ribonucleotide binding 5.60E-06 
SP_PIR_KEYWORDS nucleotide-binding 6.45E-06 
SP_PIR_KEYWORDS ATP-binding 1.09E-05 
GOTERM_MF_FAT GO:0005524~ATP binding 1.81E-05 
GOTERM_MF_FAT GO:0032559~adenyl ribonucleotide binding 3.84E-05 
   
Annotation Cluster 4 Enrichment Score: 8.909158524499384  
Category Term FDR 
GOTERM_CC_FAT GO:0031974~membrane-enclosed lumen 7.00E-11 
GOTERM_CC_FAT GO:0070013~intracellular organelle lumen 9.83E-11 
GOTERM_CC_FAT GO:0043233~organelle lumen 1.20E-10 
GOTERM_CC_FAT GO:0031981~nuclear lumen 2.30E-05 
GOTERM_CC_FAT GO:0016607~nuclear speck 6.01E-05 
GOTERM_CC_FAT GO:0016604~nuclear body 4.99E-04 
GOTERM_CC_FAT GO:0005654~nucleoplasm 5.15E-03 
   
Annotation Cluster 5 Enrichment Score: 8.144022074819771  
Category Term FDR 
GOTERM_CC_FAT GO:0044429~mitochondrial part 1.58E-10 
GOTERM_CC_FAT GO:0005759~mitochondrial matrix 2.59E-03 
GOTERM_CC_FAT GO:0031980~mitochondrial lumen 2.59E-03 
   
Annotation Cluster 6 Enrichment Score: 8.114976494819215  
Category Term FDR 
INTERPRO IPR012677:Nucleotide-binding, alpha-beta plait 1.94E-09 
INTERPRO IPR000504:RNA recognition motif, RNP-1 6.55E-09 
SP_PIR_KEYWORDS RNA-binding 2.95E-08 
SMART SM00360:RRM 9.91E-08 
GOTERM_MF_FAT GO:0003723~RNA binding 1.84E-06 
UP_SEQ_FEATURE domain:RRM 1 1.36E-03 
UP_SEQ_FEATURE domain:RRM 2 1.36E-03 
   
Annotation Cluster 7 Enrichment Score: 5.577820081203797  
Category Term FDR 
GOTERM_BP_FAT GO:0016071~mRNA metabolic process 2.99E-05 
GOTERM_BP_FAT GO:0006397~mRNA processing 6.49E-05 
SP_PIR_KEYWORDS mRNA processing 6.53E-05 
GOTERM_BP_FAT GO:0008380~RNA splicing 8.83E-05 
GOTERM_BP_FAT GO:0006396~RNA processing 3.05E-04 
SP_PIR_KEYWORDS mRNA splicing 4.12E-04 
   
Annotation Cluster 8 Enrichment Score: 4.573455401588822  
Category Term FDR 
SP_PIR_KEYWORDS fatty acid metabolism 1.78E-03 
   
Annotation Cluster 9 Enrichment Score: 4.428903499912428  
Category Term FDR 
SP_PIR_KEYWORDS Flavoprotein 5.53E-05 
GOTERM_MF_FAT GO:0050662~coenzyme binding 2.56E-03 
SP_PIR_KEYWORDS FAD 2.78E-03 
   
Annotation Cluster 
11 
Enrichment Score: 3.7314344007433613  
Category Term FDR 
GOTERM_CC_FAT GO:0005777~peroxisome 9.14E-04 
GOTERM_CC_FAT GO:0042579~microbody 9.14E-04 
   
Annotation Cluster 
47 
Enrichment Score: 1.4911957984288633  
Category Term FDR 
SP_PIR_KEYWORDS nucleus 2.20E-04 
 
FDR: false discovery rate. 
 
Appendix Table S5. P-values from statistical tests. 
 
Figure P-value 
 Vehicle versus TUG-891 
1A 1.5 wks: 0.0373 (*) 
2.5 wks: 0.0047  (**) 
1B 0.75 wks: 0.0302 (*) 
1.5 wks: 0.0016 (**) 
2.5 wks: 0.0001(***) 
1C 2.5 wks: 0.0122 (*) 
1D 2 wks: 0.0020 (**) 
1E Dark: 0.0045 (**) 
1F Light: 0.0433 (*) 
Dark: 0.0221 (*) 
1G Dark: 0.0040 (*) 
 Vehicle versus TUG-891 
2A 0.0075 (**) 
2B 0.0014 (**) 
2C 0.0000 (***) 
2D iBAT: 0.0002 (***) 
gWAT: 0.0000 (***) 
Liver: 0.0093 (*) 
 Vehicle versus WT 
TUG-891 
Vehicle versus KO TUG-
891 
WT TUG-891 versus 
KO TUG-891 
3A 12 d: 0.0163 (*) n.s. n.s. 
3B 12 d: 0.0224 (*) n.s. n.s. 
3C 6-12 d: 0.0094 (**) 6-12 d: 0.0260 (*) n.s. 
3F Dark: 0.0349 (*) n.s. n.s. 
 Vehicle versus WT 
TUG-891 
Vehicle versus KO TUG-
891 
WT TUG-891 versus 
KO TUG-891 
4A iBAT: 0.0000 (***) 
sBAT: 0.0000 (***) 
iBAT: 0.0192 (*) 
sBAT: 0.0001 (***) 
iBAT: 0.0000 (***) 
sBAT: 0.0000 (***) 
4B iBAT: 0.0290 (*) 
sBAT: 0.0000 (***) 
n.s. iBAT: 0.006283 (**) 
sBAT: 0.0000 (***) 
4C iBAT: 0.0000 (***) 
sWAT: 0.0149 (*) 
Liver: 0.0024 (**) n.d. 
 
 Vehicle versus TUG-891 
5C Sncg: 0.0118 (*) 
Mlxipl: 0.0368 (*) 
5D Glut4: 0.0453 (*) 
Insr: 0.0007 (***) 
Adcy4: 0.0092 (**) 
5E Acc1: 0.0353 (*) 
Acc2: 0.0213 (*) 
Fas: 0.0158 (*) 
Scd2: 0.0340 (*) 
Hsl: 0.0021 (**) 
Atgl: 0.0353 (*) 
Pnpla3: 0.0047 (**) 
Apoc1: 0.0062 (**) 
 Vehicle versus CL 
6A – Gpr120 0.0028 (**) 
6A – Ucp1 0.0016 (**) 
 Undiff versus Diff Undiff versus Diff + CL Diff versus Diff + CL 
6B – Gpr120 n.d. n.d. BA: 0.0000 (***) 
6B – Ucp1 n.d. n.d. BA: 0.0000 (***) 
 WT vehicle versus WT 
TUG-891 
WT vehicle versus KO 
vehicle 
WT vehicle versus KO 
TUG-891 
6C Day 0: n.d. 
Day 7: 0.0015 (**) 
Day 0: n.d. 
Day 3: 0.0050 (**) 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
Day 0: n.d. 
Day 3: 0.0052 (**) 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
6D – aP2 Day 0: n.d. 
 
Day 0: n.d. 
Day 3: 0.099 (**) 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
Day 0: n.d. 
Day 3: 0.0017 (**) 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
6D – Ucp1 Day 0: n.d. 
 
Day 0: n.d. 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
Day 0: n.d. 
Day 7: 0.0001 (***) 
Day 9: 0.0001 (***) 
 TUG-891 versus vehicle TUG-891 versus TUG-
891 + AH7614 
TUG-891 + AH7614 
versus vehicle 
7A 23 min: 0.0001 (***) 
30 min: 0.0000 (***) 
38 min: 0.0000 (***) 
45 min: 0.0000 (***) 
23 min: 0.0033 (##) 
30 min: 0.0006 (###) 
38 min: 0.0013 (##) 
45 min: 0.0017 (##) 
n.d. 
 TUG-891 versus vehicle TUG-891 versus TUG-
891 + BAPTA 
TUG-891 + BAPTA 
versus vehicle 
7D 23 min: 0.0005 (***) 
30 min: 0.0009 (***) 
38 min: 0.0004 (***) 
45 min: 0.0003 (***) 
53 min: 0.0002 (***) 
60 min: 0.0000 (***) 
23 min: 0.0138 (#) 
30 min: 0.0415 (#) 
38 min: 0.0334 (#) 
45 min: 0.0211 (#) 
53 min: 0.0238 (#) 
60 min: 0.0288 (#) 
n.d. 
 Basal versus 10 min 
7F TUG-891: 0.0094 (**) 
 Vehicle versus TUG-891 
S3A 0.0483 (*) 
S3F Scd1: 0.0001 (***) 
S3G Acc1: 0.0455 (*) 
Scd1: 0.0267 (*) 
Ccnb: 0.0149 (*) 
SGH Dgat2: 0.0441 (*) 
Ccna: 0.0003 (***) 
Ccnb: 0.0037 (**) 
Mki67: 0.0010 (***) 
Ucp1: 0.0157 (*) 
 Vehicle versus TUG-891 
S4C 0.0227 (*) 
 WT vehicle versus WT 
TUG-891 
WT vehicle versus KO 
vehicle 
WT vehicle versus KO 
TUG-891 
S6A Liver: 0.0000 (***) 
iBAT: 0.0023 (**) 
n.s. Liver: 0.0000 (***) 
S6B n.s. n.s. Liver: 0.0444 (*) 
 Vehicle versus CL 
S8A 0.0362 (*) 
S8D 0.0005 (***) 
 WT TUG-891 versus UCP1 KO TUG-891 
S9A 10 µM: 0.0092 (**) 
20 µM: 0.0144 (*) 
30 µM: 0.0337 (*) 
40 µM: 0.0211 (*) 
60 µM: 0.0143 (*) 
90 µM: 0.0003 (***) 
100 µM: 0.0002 (***) 
 WT 1 mM GDP versus WT 3 mM GDP 
S9B 20 µM: 0.0359 (*) 
 40 µM: 0.0402 (*) 
50 µM: 0.0074 (**) 
60 µM: 0.0364 (*) 
80 µM: 0.0121 (*) 
90 µM: 0.0064 (**) 
100 µM: 0.0112 (*) 
110 µM: 0.0214 (*) 
 Vehicle versus TUG-891 Vehicle versus forskolin TUG-891 versus 
forskolin 
S9D n.s. 0.0211 (*) n.d. 
 
N.s.: non-significant, n.d: non-determined. All P-values are rounded to 4 decimals. 
 
  
Appendix Figure S1. TUG-891 non-significantly affects gene expression in skeletal muscle. 
Expression of markers for inflammation (Cd68 and Lgals3) fibrosis (Ctgf), atrophy (Gadd45a and 
Murf1) and regeneration (Myog) were determined in skeletal muscle tissue of mice treated with 
vehicle or TUG-891 by qRT-PCR. Data represent means ± SEM (n = 8 per group). 
 
 
 
Appendix Figure S2. TUG-891 does not affect energy expenditure or physical activity levels. 
Energy expenditure (EE) (A) and physical activity (B) were determined by housing the mice 
individually in metabolic cages. Injection of TUG-891 or vehicle is indicated by dotted lines, and light 
and grey areas represent the light and dark phase, respectively. For bar graph analysis, mean results in 
the light and dark phase were calculated. Data represent means ± SEM (n = 8 per group). 
 
 
Appendix Figure S3. TUG-891 increases gene expression of markers for proliferation and 
thermogenesis in WAT. Plasma triglycerides (TG) (A), protein levels of UCP1, pHSL563 and pPKA 
substrates in BAT (B-E), and gene expression markers for lipolysis, lipogenesis, proliferation and 
thermogenesis in BAT (F) and WAT (G-H) were determined in vehicle and TUG-891-treated mice. 
Data represent means ± SEM (n = 8 per group). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to 
the vehicle group, according to the two-tailed unpaired Student’s T test. The exact P-value for each 
significant difference can be found in Appendix Table S5. 
 
Appendix Figure S4. TUG-891 increases protein expression of UCP1 in gWAT. Representative 
images of UCP1 immunostained interscapular BAT (iBAT, A), subcutaneous WAT (sWAT, B) and 
gonadal WAT (gWAT, C) of mice treated with vehicle or the GPR120 agonist TUG-891. Stained 
slides were digitalized and relative UCP1 staining per area was analysed using ImageJ software. Data 
represent means ± SEM (n = 8 per group). * P < 0.05 compared to the vehicle group, according to the 
two-tailed unpaired Student’s T test. The exact P-value for each significant difference can be found in 
Appendix Table S5. 
 
 
 
 
 
 
 
Appendix Figure S5. Respiratory exchange ratio and fat oxidation is similar between wild type 
and GPR120-deficient mice. Respiratory exchange ratio (RER) (A) and fat oxidation (B) was 
determined by housing GPR120 KO mice (n = 6) and WT littermates (n = 13) in metabolic cages. 
Light and grey areas represent the light and dark phase, respectively. For bar graph analysis, mean 
results in light and dark phase were calculated. Data represent means ± SEM. 
 
 
  
Appendix Figure S6. TUG-891 increases whole organ uptake of fatty acids by BAT. WT and 
GPR120 KO mice treated with vehicle or the GPR120 agonist TUG-891 were intravenously injected 
with glycerol tri[3H]oleate ([3H]TO)-labeled lipoprotein-like emulsion particles and 
[14C]deoxyglucose ([14C]DG). After 15 min, mice were sacrificed and uptake of [3H]TO- and 
[14C]DG-derived radioactivity (A-B) per whole organ was determined in organs that were dissected 
quantitatively, including gonadal WAT (gWAT) and interscapular BAT (iBAT). Data represent 
means ± SEM (n = 6-8 per group). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to the vehicle 
group or indicated control group, according to two-way ANOVA with Tukey’s post hoc test (A-B). 
The exact P-value for each significant difference can be found in Appendix Table S5. 
 
 
 
 
 
 
 
 
 
Appendix Figure S7. Gpr120 is most highly expressed in BAT. Gpr120 gene expression was 
determined in various tissues of FVB/N female mice, including brown adipose tissue (BAT), 
subcutaneous white adipose tissue (sWAT) and gonadal white adipose tissue (gWAT). Data represent 
means ± SEM (n = 3). 
 
Appendix Figure S8. Gene expression profiles of aP2, Cidea, Pref1 and Adrb3 validate the 
immortalized murine brown adipocyte cell line. Immortalized murine brown adipocytes were 
differentiated for 0, 2, 4, 6, or 7 days after which expression of aP2 (A), Cidea (B), Pref1 (C), and 
Adrb3 (D) was determined by qRT-PCR. On day 7, a subset of adipocytes was additionally stimulated 
with CL (10 µM). Data represent means ± SEM (n = 3). * P < 0.05, *** P < 0.001 compared to the 
vehicle group, according to the two-tailed unpaired Student’s T test. The exact P-value for each 
significant difference can be found in Appendix Table S5. 
 
Appendix Figure S9. TUG-891 activates UCP1 by competitively interacting with GDP, but does 
not stimulate respiration through cAMP, ERK or AKT. Isolated mitochondria from WT and 
UCP1 KO mice (n = 4-5) were stimulated with TUG-891 or vehicle and mitochondrial oxygen 
consumption was measured (A, compilation of data shown in Figure 7B and C). TUG-891-induced 
mitochondrial respiration was measured in the presence of 1 or 3 μM GDP, in WT (B) and UCP1 KO 
(C) mitochondria (n = 3-5). Intracellular cAMP levels were measured in differentiated brown 
adipocytes pretreated with vehicle, TUG-891 (10 μM) or forskolin (10 μM) (n = 7) for 5 min. (D). 
Primary brown adipocytes (n = 2) were stimulated for 5 min with vehicle or TUG-891 (10 µM) and 
relative amounts of phosphorylated and total protein was determined by Western blotting. The amount 
of phosphorylated protein was normalized to the total amount of protein (E). Immortalized brown 
adipocytes (n = 5-6) were pretreated for 30 min with vehicle, U0126 (10 µM) or AKT1/2 kinase 
inhibitor (10 µM), after which the OCR was determined in a Seahorse XF24 analyzer. After three 
baseline measurements, either vehicle or TUG-891 (10 μM) was injected into the wells (F & G). 
Brown adipocytes were incubated with the calcium sensitive dye Fluo-4-AM for 1 h at RT, followed 
by live cell imaging with a spinning disk confocal (UltraVIEW Vox, PerkinElmer) and stimulation 
with TUG-891 (10 μM) with or without the presence of YM-254890 (0.1 μM) (H). F1/F0 represents 
peak fluorescence divided by baseline fluorescence. Data represent means ± SEM. * P < 0.05, * P < 
0.01, *** P < 0.001 compared to the control group, according to the two-tailed unpaired Student’s T 
test (A-B) or one-way ANOVA with Dunnett’s post  hoc test (C). The exact P-value for each 
significant difference can be found in Appendix Table S5. 
 
